MARKET

GNCA

GNCA

Genocea
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.090
0.000
0.00%
Closed 16:00 09/24 EDT
OPEN
2.090
PREV CLOSE
2.090
HIGH
2.157
LOW
2.070
VOLUME
126.69K
TURNOVER
--
52 WEEK HIGH
4.045
52 WEEK LOW
1.650
MARKET CAP
119.16M
P/E (TTM)
-3.4302
1D
5D
1M
3M
1Y
5Y
Genocea to Present at Upcoming Scientific and Investor Conferences
Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following virtual conferences in September.
GlobeNewswire · 09/07 23:40
Do Options Traders Know Something About Genocea (GNCA) Stock We Don't?
Zacks.com · 08/23 12:36
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 207 companies hit new 52-week lows.
Benzinga · 08/16 14:12
Genocea Biosciences EPS misses by $0.02
Genocea Biosciences (NASDAQ:GNCA): Q2 GAAP EPS of -$0.20 misses by $0.02. As of June 30, 2021, cash and cash equivalents were $60.4 million compared to $79.8 million as of December
Seekingalpha · 07/29 11:21
Genocea Provides Second Quarter 2021 Corporate Update
GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues GEN-009 neoantigen vaccine candidate shows promising long-term clinical results Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Genoc...
GlobeNewswire · 07/29 11:00
Genocea to Host Second Quarter 2021 Corporate Update Conference Call & Webcast
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its second quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, July 29 at...
GlobeNewswire · 07/22 21:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GNCA. Analyze the recent business situations of Genocea through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GNCA stock price target is 6.10 with a high estimate of 8.00 and a low estimate of 4.400.
EPS
Institutional Holdings
Institutions: 66
Institutional Holdings: 34.74M
% Owned: 60.93%
Shares Outstanding: 57.02M
TypeInstitutionsShares
Increased
11
314.71K
New
12
2.72M
Decreased
7
486.71K
Sold Out
8
459.44K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Kenneth Bate
President/Chief Executive Officer/Director
William Clark
Chief Financial Officer
Diantha Duvall
Executive Vice President
Raymond Stapleton
Chief Scientific Officer
Jessica Flechtner
Other
Girish Aakalu
Other
Thomas Davis
Independent Director
Ali Behbahani
Independent Director
Katrine Bosley
Independent Director
Jennifer Herron
Independent Director
Michael Higgins
Independent Director
George Siber
No Data
About GNCA
Genocea Biosciences, Inc. is a biopharmaceutical company developing personalized cancer immunotherapies. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, the Company can improve neoantigens for inclusion in its immunotherapies and exclude inhibitory antigens that exert an immunosuppressive effect on anti-tumor immune responses. It provides GEN-009 program, which is a neoantigen vaccine candidate. The Company is conducting a Phase 1/2a clinical trial across a range of solid tumor types. It also provides GEN-011, which is a neoantigen-specific adoptive T cell therapy.

Webull offers kinds of Genocea Biosciences Inc stock information, including NASDAQ:GNCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNCA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNCA stock methods without spending real money on the virtual paper trading platform.